Singapore, April 9 -- GC Biopharma has announcedthat the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA).

With the approval by MFDS, BARYTHRAX has become Korea's 39thnovel drug. Following the application on31 Oct 2023, GC Biopharma and KDCA successfully received the product approval from MFDS on 8th this month.

Anthrax, caused by Bacillus anthracis, is class-1 infectious disease capable of surviving extreme conditions and spreading easily through airborne transmission.If untreated, its fatality rate can reach up to 97%, making it a significant threat as a potential biological weapon.

BARYTHRAX utilise...